Actively Recruiting
U-LABA/ICS Effects on Exercise Performance, Vilanterol
Led by Morten Hostrup, PhD · Updated on 2025-04-10
30
Participants Needed
1
Research Sites
165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate
CONDITIONS
Official Title
U-LABA/ICS Effects on Exercise Performance, Vilanterol
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 39 years
- Physically active more than 5 hours weekly
- Maximal oxygen consumption classified as high or very high
You will not qualify if you...
- Diagnosed with severe asthma and treated with long-acting beta2-agonist/corticosteroid
- Abnormal ECG
- ACQ score greater than 1.5
- Severe bronchial hyperreactivity as determined by mannitol test
- FEV1/FVC ratio less than 0.7 on spirometry
- Chronic illness posing potential risk during the study
- On chronic treatment with medication that may interfere with study results
- Pregnant
- Smoker
- Donated blood within the past 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
August Krogh Building
Copenhagen, DK, Denmark, 2100
Actively Recruiting
Research Team
M
Morten Hostrup, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here